page header

Contents  ·  Introduction  ·  Learning  Objectives  ·  Textbook  ·  Lectures  ·  Procedures  ·  Final Exam  ·  Library  ·  Laboratory  ·  Pharmacy  ·  Imaging  ·  Forms  ·  Videos  ·  About  ·  Contact Us>

Dapsone (Avlosulfan)

Category:

  • Miscellaneous

Description:

  • Antiprotazoal

Indications:

  • All forms of leprosy (Hansen’s disease), except for cases of proven dapsone resistance

  • Dermatitis herpetiformis

Precautions:

  • Pregnancy category C; excreted in breast milk, may cause reaction in infants

  • Renal disease, G-6-PD deficiency

  • Anemia, severe cardiopulmonary disease, methemoglobin reductase deficiency

Adverse Reactions (Side Effects):

  • CNS: headache, insomnia, paresthesia, peripheral neuropathy, psychosis, vertigo

  • EENT: blurred vision, optic neuritis, photophobia, tinnitus

  • GI: abdominal pain, anorexia, nausea, vomiting

  • GU: nephrotic syndrome, proteinuria, renal papillary necrosis

  • HEME: agranulocytosis, aplastic anemia, hemolytic anemia

  • SKIN: drug-induced systemic lupus erythematosis, photosensitivity

Dosage:

Administered orally

  • Adult:            

    • Leprosy: PO 50-100mg daily for 3-10 years (addition of rifampin 600mg daily for 1st 6 months is recommended)

    • Dermatitis herpetiformis: PO 50mg initially; increase to 300mg daily or higher to achieve full control; reduce dosage to minimum level as soon as possible

  • Child:            

    • Leprosy: PO 1-2 mg/kg/day; max 100mg daily

Special considerations:

  • Use in conjunction with rifampin or clofazimine to prevent development of drug resistance and reduce infectiousness of patient with leprosy more quickly

  • Full therapeutic effects on leprosy may not occur for several months; compliance with dosage schedule, duration is important

 

 

 


The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks

Source: Operational Medicine 2001,  Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300

This information is provided by The Brookside Associates.  The Brookside Associates, LLC. is a private organization, not affiliated with any governmental agency. The opinions presented here are those of the author and do not necessarily represent the opinions of the Brookside Associates or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. All material presented here is unclassified.

C. 2009, 2014, All Rights Reserved

brookside associates logo

 

 

 

 

 

 

Advertise on this site